HIGHLIGHTS
- who: Carole Mercier from the University of California, Los Angeles, United States have published the paper: Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer, in the Journal: (JOURNAL) of 27/01/2022
- what: The aim of this analysis is to report survival outcomes and pattern of recurrence of patients with hormone-sensitive (HSPC) and castrate-resistant (CRPC) oligometastatic prostate cancer treated with SABR. Since immune-checkpoint inhibitor monotherapy has shown only modest benefits in the mCRPC setting, the ICE-PAC trial aimed at improving outcomes by combining the PD-L1 checkpoint . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.